FDA approves MolecuLight’s handheld fluorescence imaging device

Digital health innovators have the opportunity to take part in a programme to improve diabetes care.

MolecuLight Inc. has achieved a major regulatory milestone permitting expansion into the United States market. FDA has granted De Novo clearance for the ground-breaking wound fluorescence imaging device, the MolecuLight i:X TM.

The device digitally captures and documents fluorescence information from wounds and surrounding tissue using still images and videos in real-time. This product is optimised for use at the point-of-care. It is compact and portable, with no requirement to use contrast agents.

In the US, the MolecuLight i:X is indicated as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds at the point of care, to view and digitally record images of a wound, and view and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. The MolecuLight i:X is for prescription use only.

The device received Health Canada Medical Device License in 2015 and European CE Mark in 2016.

Dr. Ralph DaCosta, Founder, Chief Scientific Officer and Director of MolecuLight Inc said, “The MolecuLight i:X platform is a significant advancement in the management of chronic wounds, that is already revolutionizing wound care practice in Canada and Europe. Thousands of patients to date have already experienced a change in their assessment and treatment by clinicians who feel empowered by the wound fluorescence images they are seeing. As reported in multi-centered published clinical studies, clinicians used the images to inform their wound management practices in real-time, in particular, for guided wound sampling, cleaning and debridement. We’re very excited that US clinicians will soon have the same access to this device as their peers in Canada and Europe.”

Anil Amlani, CEO of MolecuLight Inc commented, “FDA marketing authorisation of the MolecuLight i:X is a monumental milestone for the wound care industry. Thanks to continued clinical studies and 17 publications to date, the clinical evidence is rapidly accumulating that the MolecuLight i:X is a must‑have device in the hands of all wound care clinicians.”

FL-image revealed both cyan fluorescing bacteria which is indicative of Pseudomonas aeruginosa (arrows) and red fluorescing bacteria (circled) which guided swabbing for accurate microbiology results. Microbiology Results: Curettage samples confirmed heavy growth of Pseudomonas aeruginosa and light growth of Staphylococcus aureus in this wound Image/Video Provided By: Ron Linden, MD, Judy Dan Research & Treatment Centre, Toronto, ON, Canada